Olympus debuts AI-driven surgical planning tool
Olympus has introduced its first AI-driven clinical decision tool in partnership with software company Ziosoft.
This application combines advanced imaging analytics and machine learning to help surgeons streamline preoperative planning and improve clinical efficiency in ambulatory surgery centers (ASCs).
Initial modules focus on liver, lung and kidney procedures. A thoracic surgery feature transforms standard CT/MRI scans into 3D models for more precise lung cancer and thoracic procedure planning. The liver tool helps general and hepatobiliary surgeons visualize blood vessels and tumors, guiding safer, tissue-preserving approaches. For kidney procedures, urologists can better gauge tumor size and location in preparation for minimally invasive nephrectomies.
Spineart and eCential Robotics secure FDA clearance
Spineart and eCential Robotics announced FDA 510(k) clearance of the Spineart Perla TL application on the new eCential Op.n robotic navigation platform. This collaboration integrates Spineart’s Perla TL Open and MIS screw systems with eCential’s navigation-specific interface and instruments, promising enhanced surgical precision and workflow efficiency.
It also broadens 3D C-arm compatibility, further benefiting ambulatory surgery centers.
“Our partnership with eCential Robotics in surgical and robotic navigation has empowered us to pursue an innovative approach that enhances precision and workflow efficiency in the operating room while utilizing our implants and instruments for spine surgery,” Jerome Trividic, CEO of Spineart, said in a press release.
Stryker unveils Mako 4
Stryker has launched its fourth-generation Mako system, a comprehensive robotic platform designed for total hip, total knee, partial knee and pine procedures. Unveiled at AAOS 2025, Mako 4 integrates the latest Q Guidance system to elevate surgical precision and streamline workflows.
A standout feature is the first-to-market robotic hip revision capability, which enhances revision total hip arthroplasty with advanced augment and screw planning and intraoperative trajectory guidance.
Additionally, Mako Spine and Mako Shoulder now join Stryker’s SmartRobotics suite, following recent FDA clearance, further expanding the platform’s reach.
CMR Surgical achieves 30,000-case milestone
CMR Surgical announced that its Versius robotic system, a smaller system more suited toward the outpatient setting, has now been used in over 30,000 surgeries worldwide, solidifying its status as the second-most adopted soft-tissue surgical robot.
Designed to support minimally invasive procedures, Versius aids in accessing challenging areas like the lungs, thymus and esophagus.
Following its FDA clearance in October, the system offers collaborative arms, customizable port placements, and an ergonomic design that mimics the human arm.
With features like 3D HD vision and user-friendly instrument control, Versius aims to reduce surgeon fatigue and improve communication within the surgical team. More than 70% of hospitals employing Versius have integrated it across multiple specialties, including urology, general surgery, gynecology and thoracic surgery, with ongoing trials in pediatric and transoral robotic procedures.
“We are proud that over 30,000 patients around the world have now benefited from Versius, as we continue to grow and deliver against our mission of transforming surgery; for good,” CMR Surgical CEO Massimiliano Colella said in a press release. “This milestone is thanks to the surgeons and hospitals who have adopted Versius with the aim of improving patient care, and our dedicated employees who are committed to giving our customers the best experience.”
Zimmer Biomet’s $1.2 billion acquisition
Zimmer Biomet announced its plan to acquire Paragon 28 for $1.2 billion, in a move to expand its portfolio in foot and ankle treatments.
Paragon 28 manufactures a range of products covering fracture care, trauma management, deformity correction and joint replacement.
“This proposed transaction further diversifies Zimmer Biomet’s portfolio outside of core orthopedics and positions us well in one of the highest growth specialized segments in musculoskeletal care, while creating cross-selling opportunities in the rapidly growing [ambulatory surgery center] space,” Zimmer Biomet CEO Ivan Tornos said in a press release.
